Skip to main content

For healthcare providers

Evira for regions and childhood obesity clinics

Childhood obesity requires long-term treatment, but a large part of the treatment takes place between visits. Evira is a digital treatment support that enables the treatment team to continuously monitor progress and direct efforts where they are most needed – within the care pathway you already have.

Treatment at home and at the clinic

At home

The child weighs themselves on a numberless smart scale. The family follows development in the app together with their treatment goals.

At the clinic

The treatment team sees development in the clinic interface and can prioritise the patients who need contact first.

Connection to national care programmes and close care

The national care programme for childhood obesity describes combined lifestyle treatment as the foundation and digital treatment support as a possible part of intensive interventions. Evira is mentioned there as a digital treatment support.

For regions, the working method is close to the development towards self-monitoring and close care: measurements take place at home, while assessment and treatment decisions remain with the treatment team.

Read more about the national care programme and KLB

Before and with Evira

Without digital supportWith Evira
Development between visits is unknown.The treatment team can continuously monitor weight development.
Weight is measured in front of the child at the clinic.The child weighs themselves at home without seeing the number.
All patients follow the same visit frequency.Contacts can be directed where the need is greatest.
The family lacks support between visits.The family has goals, visualisation and a contact path in the app.

Five questions to address before a decision

  1. 1. Which problem should be solved?

    For example, limited follow-up between visits, long waiting times or unequal access to treatment in the region.

  2. 2. Which patient group is affected?

    Age, degree of obesity, care level and number of patients in current treatment.

  3. 3. How does it fit into the care pathway?

    Which visits, contacts and decision points currently exist and what should be changed.

  4. 4. Who is responsible for what?

    The healthcare provider has care and personal data responsibility. Evira is the personal data processor and is responsible for the platform.

  5. 5. How is the result followed up locally?

    Which metrics you want to track, for example BMI-SDS development, participation and treatment continuity.

How an implementation works

  1. 1

    Review

    We review the current situation, the patient group and what you want to achieve.

  2. 2

    Agreement and data protection

    Personal data processing agreement and documentation for your risk assessment and DPIA.

  3. 3

    Team start-up

    Accounts, roles and training for the treatment team.

  4. 4

    First patients

    You start with a limited number of patients in the existing care pathway.

  5. 5

    Follow-up and scale-up

    Evaluation together with us and gradual expansion at your chosen pace.

No local installation is required and you do not need to change your journal system. Read more about implementation at the clinic

Patient data, security and responsibility

The healthcare provider is the personal data controller and retains medical responsibility. Evira is responsible for the platform as a personal data processor.

  • CE-marked medical device according to MDR, Class I
  • Evira is the personal data processor, the healthcare provider is the data controller
  • Two-factor authentication for healthcare staff
  • Encryption in transit and storage
  • Operation and storage within the EU/EEA
  • Logging and access control
  • Basis for DPIA, information security and procurement

Read more about security, patient data and responsibility

Evidence

In a pragmatic study with 107 children and adolescents using Evira, compared to 321 matched patients receiving standard treatment, the mean change in BMI-SDS was −0.30 after one year.

In the three-year follow-up, the adjusted change in BMI Z-score was −0.29 with Evira compared to −0.12 with standard treatment.

The impact on your own healthcare production and cost needs to be calculated locally based on your care pathway and patient volume. We are happy to share documentation for this calculation.

Read more about the research behind Evira

Start with the care pathway, not the technology

Book a demo and we will look together at your patient group, your patient flows and where digital follow-up would make the biggest difference.

Frequently asked questions from regions and clinics